Executives at Shire PLC speak often of the firm's strong emphasis on rare diseases, but one of its pipeline candidates for Hunter syndrome faces an unclear future after missing both the primary and key secondary endpoint in Phase II/III study.
The Dublin-based company reported Dec. 19 that SHP609, an intrathecally delivered formulation of its approved Hunter syndrome drug Elaprase (idursulfase),...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)